Medical Economics November 11, 2024
Key Takeaways
- mRNA technology holds promise for personalized cancer vaccines, but public confidence needs addressing.
- COVID-19 highlighted the need for robust vaccine distribution infrastructure and cold chain management.
- Sustained R&D investment and partnerships between public health organizations and industry are crucial for future vaccine success.
- Pfizer targets unmet medical needs with mRNA technology, exemplified by recent RSV vaccine developments.
At the Financial Times Global Pharma and Biotech Summit 2024, a panel discussed the potential of mRNA technology in developing cancer vaccines amid distrust from the public.
Vaccine R&D has always been an important part of healthcare, especially during the COVID-19 pandemic. In the post-COVID world, there are a number of investments being made in preparation of future pandemics,...
Today's Sponsors
Today's Sponsor